Loading
Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.
Jennifer Brown was principal investigator of ALPINE, which showed zanubrutinib improves progression-free survival and causes fewer cardiac events than ibrutinib in relapsed CLL, and led early work on idelalisib and the genetics of familial CLL. She directs the CLL centre at Dana-Farber and leads trials of non-covalent BTK inhibitors and BTK degraders for resistant disease.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares ALPINE, Chronic lymphocytic leukaemia.
Shares Small-molecule kinase inhibitors and the tag trialist.
Shares Dana-Farber Brigham Cancer Center and the tag trialist.